Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer

NCT00711191 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00711191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00711191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2011
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasm